CN111836801B - 用于抑制tnik的化合物及其医疗用途 - Google Patents
用于抑制tnik的化合物及其医疗用途 Download PDFInfo
- Publication number
- CN111836801B CN111836801B CN201980016887.4A CN201980016887A CN111836801B CN 111836801 B CN111836801 B CN 111836801B CN 201980016887 A CN201980016887 A CN 201980016887A CN 111836801 B CN111836801 B CN 111836801B
- Authority
- CN
- China
- Prior art keywords
- pyrazol
- amine
- phenyl
- tolyl
- methyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/38—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20180015170 | 2018-02-07 | ||
| KR10-2018-0015170 | 2018-02-07 | ||
| PCT/KR2019/001404 WO2019156439A1 (en) | 2018-02-07 | 2019-01-31 | Compounds for inhibiting tnik and medical uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN111836801A CN111836801A (zh) | 2020-10-27 |
| CN111836801B true CN111836801B (zh) | 2024-02-02 |
Family
ID=67548327
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201980016887.4A Active CN111836801B (zh) | 2018-02-07 | 2019-01-31 | 用于抑制tnik的化合物及其医疗用途 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US11485711B2 (cg-RX-API-DMAC7.html) |
| EP (2) | EP4477271B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7302794B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR102725207B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN111836801B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2019217094B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3090233A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2019156439A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7302794B2 (ja) | 2018-02-07 | 2023-07-04 | コリア リサーチ インスティチュート オブ ケミカル テクノロジー | Tnikを阻害するための化合物及びその医学的使用 |
| CN111788183B (zh) * | 2018-02-07 | 2024-02-23 | 韩国化学硏究院 | 用于抑制tnik的杂环融合苯基化合物及其医疗用途 |
| CN111718310B (zh) * | 2019-08-19 | 2021-06-11 | 中国药科大学 | 苯基取代的五元杂环类化合物及其制备方法、用途和药物组合物 |
| WO2022034587A1 (en) * | 2020-08-10 | 2022-02-17 | Tnik Therapeutics Ltd | Traf2- AND Nck-INTERACTING KINASE (TNIK) INHIBITORS AND USES THEREOF |
| JP7843071B2 (ja) * | 2021-11-12 | 2026-04-09 | バイオポーラー ヨータン(グァンドン) ファーマシューティカル カンパニー,リミテッド | Drak2阻害剤およびその製造方法と使用 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0248523A1 (en) * | 1986-05-07 | 1987-12-09 | FISONS plc | Pyrazoles |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8611102D0 (en) * | 1986-05-07 | 1986-06-11 | Fisons Plc | Heterocyclic compounds |
| BR0110302A (pt) | 2000-04-18 | 2003-01-14 | Agouron Pharma | Compostos de pirazol para inibição de proteìnas cinase, sal e pró-droga farmaceuticamente aceitável, metabólito farmaceuticamente ativo ou sal farmaceuticamente aceitável de metabólito, composição farmacêutica, método de tratamento de condição doentia em mamìferos mediada pela atividade de proteìna cinase, método de modulação ou inibição da atividade de um receptor de proteìna cinase |
| JP2006528661A (ja) | 2003-07-25 | 2006-12-21 | ファイザー・インク | アミノピラゾール化合物およびchk1阻害剤としての使用 |
| WO2009030890A1 (en) | 2007-09-03 | 2009-03-12 | University Court Of The University Of Dundee | Pyrimidine compounds for the treatment of cancer, septic shock and/or primary open angle glaucoma |
| US20100216795A1 (en) | 2008-12-01 | 2010-08-26 | Tesshi Yamada | Tnik inhibitor and the use |
| GB0903759D0 (en) | 2009-03-04 | 2009-04-15 | Medical Res Council | Compound |
| GB201402277D0 (en) | 2014-02-10 | 2014-03-26 | Sentinel Oncology Ltd | Pharmaceutical compounds |
| KR101663277B1 (ko) * | 2015-03-30 | 2016-10-06 | 주식회사 녹십자 | TNIK, IKKε 및 TBK1 억제제로서의 피라졸계 유도체 및 이를 포함하는 약학적 조성물 |
| EP3747302A3 (en) | 2015-05-29 | 2021-03-03 | Nike Innovate C.V. | Article of footwear comprising motorized tensioning device with split spool system |
| JP7302794B2 (ja) | 2018-02-07 | 2023-07-04 | コリア リサーチ インスティチュート オブ ケミカル テクノロジー | Tnikを阻害するための化合物及びその医学的使用 |
-
2019
- 2019-01-31 JP JP2020542093A patent/JP7302794B2/ja active Active
- 2019-01-31 CN CN201980016887.4A patent/CN111836801B/zh active Active
- 2019-01-31 EP EP24201292.0A patent/EP4477271B1/en active Active
- 2019-01-31 EP EP19751775.8A patent/EP3749648B1/en active Active
- 2019-01-31 KR KR1020207024628A patent/KR102725207B1/ko active Active
- 2019-01-31 WO PCT/KR2019/001404 patent/WO2019156439A1/en not_active Ceased
- 2019-01-31 US US16/967,844 patent/US11485711B2/en active Active
- 2019-01-31 CA CA3090233A patent/CA3090233A1/en active Pending
- 2019-01-31 AU AU2019217094A patent/AU2019217094B2/en active Active
-
2022
- 2022-09-07 US US17/939,147 patent/US11767297B2/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0248523A1 (en) * | 1986-05-07 | 1987-12-09 | FISONS plc | Pyrazoles |
Non-Patent Citations (1)
| Title |
|---|
| Prediction of Multiple Binding Modes of the CDK2 Inhibitors, Anilinopyrazoles, Using the Automated Docking Programs GOLD, FlexX, and LigandFit: An Evaluation of Performance;Hideyuki Sato,等;《J. Chem. Inf. Model.》;20061231;第46卷;2552-2562 * |
Also Published As
| Publication number | Publication date |
|---|---|
| EP3749648A1 (en) | 2020-12-16 |
| CN111836801A (zh) | 2020-10-27 |
| US20230039679A1 (en) | 2023-02-09 |
| JP7302794B2 (ja) | 2023-07-04 |
| AU2019217094A1 (en) | 2020-09-17 |
| EP4477271B1 (en) | 2026-05-13 |
| US11767297B2 (en) | 2023-09-26 |
| EP3749648C0 (en) | 2024-10-30 |
| US20210047277A1 (en) | 2021-02-18 |
| EP4477271A2 (en) | 2024-12-18 |
| WO2019156439A1 (en) | 2019-08-15 |
| KR20200108078A (ko) | 2020-09-16 |
| KR102725207B1 (ko) | 2024-11-01 |
| EP4477271A3 (en) | 2025-04-30 |
| EP3749648B1 (en) | 2024-10-30 |
| CA3090233A1 (en) | 2019-08-15 |
| EP3749648A4 (en) | 2021-11-24 |
| JP2021512873A (ja) | 2021-05-20 |
| AU2019217094B2 (en) | 2023-04-06 |
| US11485711B2 (en) | 2022-11-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11767297B2 (en) | Compounds for inhibiting TNIK and medical uses thereof | |
| TWI473792B (zh) | New quinoline compounds and their use | |
| JP6464139B2 (ja) | ブロモドメイン含有タンパク質の阻害のための方法および組成物 | |
| CN103130735B (zh) | 吲哚胺2,3-双加氧酶调节剂及其用法 | |
| WO2021088787A1 (zh) | 作为axl抑制剂的喹唑啉类化合物 | |
| JP6294277B2 (ja) | Hec1活性の調節因子およびそのための方法 | |
| JP2022530097A (ja) | がんを処置するためのアシルスルホンアミド類 | |
| JP7109919B2 (ja) | Usp7阻害剤化合物及び使用方法 | |
| JP2013501792A (ja) | Wnt/b−カテニンシグナル伝達経路阻害剤としてのインダゾールおよびその治療的使用 | |
| WO2015188747A1 (zh) | 作为egfr抑制剂的苯基取代的三嗪类化合物及其应用 | |
| CN103108867A (zh) | 噁二唑化合物及其制备和用途 | |
| CN116715625A (zh) | 作为蛋白激酶抑制剂的杂芳基化合物 | |
| JP2018108998A (ja) | Pi−3キナーゼ阻害剤の投与レジメン | |
| TW200819434A (en) | 1-(het)aryl-3-[hetaryl-piperidin-4-yl]-thioureas as modulators of the EP2 receptor | |
| CN111788183B (zh) | 用于抑制tnik的杂环融合苯基化合物及其医疗用途 | |
| TW200404062A (en) | Imidazolamino compounds | |
| HK40039190B (en) | N-(phenyl)-5-(phenyl)-1h-pyrazol-3-amine derivatives as tnik inhibitors for use in the treatment of cancer | |
| HK40039190A (en) | N-(phenyl)-5-(phenyl)-1h-pyrazol-3-amine derivatives as tnik inhibitors for use in the treatment of cancer | |
| KR102776660B1 (ko) | 벤조다이옥세인 유도체 화합물 및 이의 의약 용도 | |
| KR101920163B1 (ko) | 항암용 약학 조성물 | |
| HK40039216A (en) | N-(5-(phenyl)-1h-pyrazol-3-yl)-1h-indol-5-amine derivatives as tnik inhibitors for the treatment of cancer | |
| HK40039216B (en) | N-(5-(phenyl)-1h-pyrazol-3-yl)-1h-indol-5-amine derivatives as tnik inhibitors for the treatment of cancer | |
| WO2017097215A1 (zh) | 内嵌脲类结构的wnt通路抑制剂 | |
| WO2014190872A1 (zh) | 一种含硒化合物及其医药用途 | |
| HK1248684B (en) | Usp7 inhibitor compounds and methods of use |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |